Unveiling the role of circulating periostin in patients with idiopathic pulmonary fibrosis: A prognostic meta-analysis

Wasfi Alghwyeen; Shrouk F. Mohamed; Ahmed Shamil Hashim; Abdelrahman M.  Tawfik; Ahmed  Kertam

doi:10.36141/svdld.vi.16980

Authors

Wasfi Alghwyeen AL- Nadeem Hospital, Ministry Of Health, Amman, Jordan
Shrouk F. Mohamed Faculty of Medicine, Alexandria University, Alexandria, Egypt
Ahmed Shamil Hashim College of Medicine, University of Baghdad, Iraq
Abdelrahman M. Tawfik Faculty of Medicine, Alexandria University, Alexandria, Egypt
Ahmed Kertam Faculty of Medicine, Ain-Shams University, Cairo, Egypt

Keywords:

IPF; periostin; meta analysis.

Abstract

Background: Periostin measurement has been suggested as a noninvasive biomarker for assessing the likelihood of IPF progression and predicting patient outcomes, but these results aren't entirely consistent. Therefore, we conducted a meta-analysis to study the relation between serum periostin and IPF.

Methods: We conducted a comprehensive search in major electronic biomedical databases of (PubMed, Scopus, Cochrane Library, EMBASE and Web of Science) spanning from inception to September 2024. Meta-analysis of included studies was done, and quantitative data were pooled as standardized mean difference (SMD), odd rations (ORs) and coefficient (r) values , with corresponding 95% confidence intervals (CIs).

Results: Eleven articles were included in final meta-analysis. Our results showed that there was no significant difference in periostin levels between IPF patients and healthy controls (SMD: 2.59, 95% CI: -0.59 to 5.77, p= 0.11). Moreover, it was shown that IPF patients with a progressive disease have higher periostin levels compared to those who remain stable (SMD: 0.52, 95% CI: 0.29 to 0.75, p<0.0001). In addition to, higher serum periostin levels were significantly associated with shortened overall survival among IPF patients (RR: 3.70, 95% CI: 1.84 to 7.43, p<0.0001). Finally, there was a significant negative correlation between periostin levels and relative decline in DLCO and VC over the follow-up period (COR: -0.36, 95% CI, -0.58 to -0.10), (COR: -0.49, 95% CI, -0.63 to -0.34) respectively.

Conclusions: This study concludes that periostin may be a valuable biomarker for predicting prognosis in IPF patients.

References

1. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976 Dec;85(6):769–88.

2. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44–68.

3. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15;183(4):431–40.

4. Sokai A, Tanizawa K, Handa T, Kanatani K, Kubo T, Ikezoe K, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res. 2017 Jul;3(3):00019–2016.

5. White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR, et al. Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2016 Nov 15;194(10):1242–51.

6. Sonnenberg-Riethmacher E, Miehe M, Riethmacher D. Periostin in Allergy and Inflammation. Front Immunol. 2021;12:722170.

7. Okamoto M, Izuhara K, Ohta S, Ono J, Hoshino T. Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis. Adv Exp Med Biol. 2019;1132:79–87.

8. Izuhara K, Nunomura S, Nanri Y, Ogawa M, Ono J, Mitamura Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017 Dec;74(23):4293–303.

9. O’Dwyer DN, Moore BB. The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017 Dec;74(23):4305–14.

10. Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H, et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One. 2017;12(3):e0174547.

11. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010 Sep;25(9):603–5.

12. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018 Jun;27(6):1785–805.

13. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014 Dec 19;14:135.

14. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011 May;37(5):1119–27.

15. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15;303(12):L1046-1056.

16. Tajiri M, Okamoto M, Fujimoto K, Johkoh T, Ono J, Tominaga M, et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir Investig. 2015 Mar;53(2):73–81.

17. Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003 May;162(5):1495–502.

18. Hardie WD, Hagood JS, Dave V, Perl AKT, Whitsett JA, Korfhagen TR, et al. Signaling pathways in the epithelial origins of pulmonary fibrosis. Cell Cycle. 2010 Jul 15;9(14):2769–76.

19. Israël-Biet D, Bernardinello N, Pastré J, Tana C, Spagnolo P. High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities. Diagnostics (Basel). 2024 Feb 11;14(4):395.

20. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016 Mar 4;17:23.

21. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008 Apr 29;5(4):e93.